Yervoy (ipilimumab) is an immune checkpoint inhibitor used in the treatment of melanoma, a type of skin cancer. While the sources provided do not specifically discuss the treatment of Yervoy overdose, they provide information on its use, side effects, and long-term effects. It is important to note that the treatment of Yervoy overdose should be conducted under the supervision of a healthcare professional, as they are best equipped to manage such situations.

Yervoy is typically administered intravenously and works by targeting and blocking a protein called CTLA-4, which helps the immune system recognize and attack cancer cells. By inhibiting this protein, Yervoy helps to unleash the immune system's response against cancer cells [1].

The sources also highlight some potential side effects of Yervoy treatment. These can include immune-related adverse events (irAEs) such as skin rash, diarrhea, colitis, hepatitis, and endocrine dysfunction. These side effects can range from mild to severe and may require appropriate management, including the use of corticosteroids or other immunosuppressive medications [2].

Additionally, the long-term effects of immune checkpoint inhibitors like Yervoy are discussed in one of the sources. It mentions that while these drugs have shown significant benefits in the treatment of melanoma, they can also have long-lasting effects on the immune system. These effects can include autoimmune diseases, such as hypothyroidism, hypophysitis, and diabetes, which may require ongoing management [2].

However, it is important to note that the sources provided do not specifically address the treatment of Yervoy overdose. In the event of an overdose, it is crucial to seek immediate medical attention. Healthcare professionals will evaluate the situation and provide appropriate treatment based on the individual's condition. Treatment may involve supportive care, close monitoring of vital signs, and potentially the administration of medications to manage any symptoms or complications that may arise.

In conclusion, while the sources provide valuable information about Yervoy and its use in the treatment of melanoma, they do not specifically address the treatment of Yervoy overdose. It is essential to consult a healthcare professional for appropriate management in case of an overdose.

Sources:
[1] Drug Patent Watch. (n.d.). Yervoy. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] National Cancer Institute. (2021). Immune Checkpoint Inhibitors for Melanoma: Long-Term Side Effects. Retrieved from https://www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects
[3] National Center for Biotechnology Information. (2020). Medical Management of Chemical Casualties Handbook. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK567801/